National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.
Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Clin J Am Soc Nephrol. 2021 Nov;16(11):1639-1651. doi: 10.2215/CJN.00320121. Epub 2021 Sep 22.
Membranoproliferative GN and C3 glomerulopathy are rare and overlapping disorders associated with dysregulation of the alternative complement pathway. Specific etiologic data for pediatric membranoproliferative GN/C3 glomerulopathy are lacking, and outcome data are based on retrospective studies without etiologic data.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 80 prevalent pediatric patients with membranoproliferative GN/C3 glomerulopathy underwent detailed phenotyping and long-term follow-up within the National Registry of Rare Kidney Diseases (RaDaR). Risk factors for kidney survival were determined using a Cox proportional hazards model. Kidney and transplant graft survival was determined using the Kaplan-Meier method.
Central histology review determined 39 patients with C3 glomerulopathy, 31 with immune-complex membranoproliferative GN, and ten with immune-complex GN. Patients were aged 2-15 (median, 9; interquartile range, 7-11) years. Median complement C3 and C4 levels were 0.31 g/L and 0.14 g/L, respectively; acquired (anticomplement autoantibodies) or genetic alternative pathway abnormalities were detected in 46% and 9% of patients, respectively, across all groups, including those with immune-complex GN. Median follow-up was 5.18 (interquartile range, 2.13-8.08) years. Eleven patients (14%) progressed to kidney failure, with nine transplants performed in eight patients, two of which failed due to recurrent disease. Presence of >50% crescents on the initial biopsy specimen was the sole variable associated with kidney failure in multivariable analysis (hazard ratio, 6.2; 95% confidence interval, 1.05 to 36.6; 0.05). Three distinct C3 glomerulopathy prognostic groups were identified according to presenting eGFR and >50% crescents on the initial biopsy specimen.
Crescentic disease was a key risk factor associated with kidney failure in a national cohort of pediatric patients with membranoproliferative GN/C3 glomerulopathy and immune-complex GN. Presenting eGFR and crescentic disease help define prognostic groups in pediatric C3 glomerulopathy. Acquired abnormalities of the alternative pathway were commonly identified but not a risk factor for kidney failure.
膜增生性 GN 和 C3 肾小球病是罕见且重叠的疾病,与替代补体途径的失调有关。儿科膜增生性 GN/C3 肾小球病的具体病因数据缺乏,而结局数据则基于没有病因数据的回顾性研究。
设计、地点、参与者和测量:共有 80 例患有膜增生性 GN/C3 肾小球病的儿科患者在国家罕见肾脏疾病登记处(RaDaR)中进行了详细的表型分析和长期随访。使用 Cox 比例风险模型确定肾脏生存的危险因素。使用 Kaplan-Meier 方法确定肾脏和移植移植物的生存情况。
中心组织学回顾确定 39 例 C3 肾小球病患者、31 例免疫复合物性膜增生性 GN 患者和 10 例免疫复合物性 GN 患者。患者年龄为 2-15 岁(中位数 9 岁,四分位距 7-11 岁)。中位补体 C3 和 C4 水平分别为 0.31 g/L 和 0.14 g/L;在所有组中,包括免疫复合物性 GN 患者,46%和 9%的患者分别检测到获得性(抗补体自身抗体)或遗传替代途径异常。中位随访时间为 5.18 年(四分位距 2.13-8.08 年)。11 名患者(14%)进展为肾衰竭,8 名患者接受了 9 例移植,其中 2 例因疾病复发而失败。在多变量分析中,初始活检标本上存在 >50%的新月体是唯一与肾衰竭相关的变量(风险比,6.2;95%置信区间,1.05 至 36.6;0.05)。根据初始活检标本上的 eGFR 和 >50%的新月体,确定了 3 个不同的 C3 肾小球病预后组。
新月体疾病是一个国家队列中儿科膜增生性 GN/C3 肾小球病和免疫复合物性 GN 患者肾衰竭的关键危险因素,且 eGFR 和新月体疾病有助于确定儿科 C3 肾小球病的预后组。替代途径获得性异常虽然常见,但不是肾衰竭的危险因素。